标题
Persistent androgen receptor addiction in castration-resistant prostate cancer
作者
关键词
Prostate cancer, Castration-resistant prostate cancer, Androgen receptor, Androgen receptor splice variant, Drug resistance, Signaling pathway
出版物
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-11-13
DOI
10.1186/s13045-015-0225-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
- (2015) C. Liu et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer
- (2015) Daniel Tamae et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents
- (2015) Gaurav Joshi et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
- (2015) Lei Chang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
- (2015) Maha Hussain et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
- (2015) Arun A. Azad et al. EUROPEAN UROLOGY
- SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC).
- (2015) Jennifer Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer.
- (2015) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Targeting the MLL complex in castration-resistant prostate cancer
- (2015) Rohit Malik et al. NATURE MEDICINE
- A multicenter study showsPTENdeletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
- (2015) Dean A. Troyer et al. PROSTATE
- Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
- (2015) H H Cheng et al. PROSTATE CANCER AND PROSTATIC DISEASES
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
- (2015) D. T. Miyamoto et al. SCIENCE
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
- (2015) M. T. Schweizer et al. Science Translational Medicine
- EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
- (2015) Lucas J. Brand et al. Oncotarget
- Progress in Understanding What Is Being Statin(ed) in Prostate Cancer
- (2015) Jorge D. Ramos et al. JAMA Oncology
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer
- (2015) Lauren C. Harshman et al. JAMA Oncology
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Androgen receptor phosphorylation: biological context and functional consequences
- (2014) Yulia Koryakina et al. ENDOCRINE-RELATED CANCER
- Minireview: SLCO and ABC Transporters: A Role for Steroid Transport in Prostate Cancer Progression
- (2014) Eunpi Cho et al. ENDOCRINOLOGY
- Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
- (2014) L Rhoda Molife et al. Future Oncology
- Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer
- (2014) Yin Cao et al. INTERNATIONAL JOURNAL OF CANCER
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
- (2014) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Steroid Receptors Aplenty in Prostate Cancer
- (2014) Nima Sharifi NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
- (2014) Elahe A. Mostaghel et al. PLoS One
- Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone
- (2014) Daniel L. Suzman et al. PROSTATE
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
- (2013) Hielke J. Meulenbeld et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
- (2013) Andrew J. Armstrong et al. Clinical Genitourinary Cancer
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
- (2013) Nima Sharifi ENDOCRINOLOGY
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
- (2013) Andy J. Liedtke et al. JOURNAL OF MEDICINAL CHEMISTRY
- NF- B2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
- (2013) N. Nadiminty et al. MOLECULAR CANCER THERAPEUTICS
- Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets
- (2013) J. M. Drake et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors
- (2012) Elahe A. Mostaghel et al. PLoS One
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes
- (2011) J. L. Wright et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2011) Ming Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
- (2011) Peter S. Nelson JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
- (2011) Jayaprakash Karkera et al. PROSTATE
- A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
- (2011) Young E. Whang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
- (2011) Glenn Liu et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
- (2010) Srikala S. Sridhar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- 3β-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate Cancer
- (2010) Kristen Evaul et al. ENDOCRINOLOGY
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- HER-2/neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis
- (2010) Ary Serpa Neto et al. JOURNAL OF UROLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
- (2009) A M Traish et al. BRITISH JOURNAL OF CANCER
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer
- (2008) Nima Sharifi et al. BJU INTERNATIONAL
- A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
- (2008) Mary-Ellen Taplin et al. BJU INTERNATIONAL
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
- (2008) A. Hamada et al. CLINICAL CANCER RESEARCH
- Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
- (2008) M.-L. Zhu et al. ENDOCRINE-RELATED CANCER
- Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation
- (2008) Wenyan Lu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Regulation of Akt/FOXO3a/GSK-3β/AR Signaling Network by Isoflavone in Prostate Cancer Cells
- (2008) Yiwei Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
- (2008) Y Wang et al. ONCOGENE
- The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations
- (2008) A. Dubrovska et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started